International Journal of Gynecology & Obstetrics
Volume 93, Issue 1 , Pages 28-32 , April 2006

The effects of analytical factors on second trimester risk estimations

  • M.A. Serdar

      Affiliations

    • Department of Clinical Chemistry, Gulhane Military Medical Academy, Ankara, Turkey
    • Corresponding Author InformationCorresponding author. Gulhane School of Medicine, Department of Clinical Chemistry, Etlik-06018, Ankara, Turkey. Tel./fax: +90 312 3043300.
    • ,
  • L. Tütüncü

      Affiliations

    • Department of Obstetrics and Gynecology, Gulhane Military Medical Academy, Istanbul, Turkey
    • ,
  • A. Olgun

      Affiliations

    • Department of Clinical Chemistry, Gulhane Military Medical Academy, Ankara, Turkey
    • ,
  • A. Haşimi

      Affiliations

    • Department of Clinical Chemistry, Gulhane Military Medical Academy, Ankara, Turkey
    • ,
  • T. Ozgurtaş

      Affiliations

    • Department of Clinical Chemistry, Gulhane Military Medical Academy, Ankara, Turkey
    • ,
  • M.K. Erbil

      Affiliations

    • Department of Clinical Chemistry, Gulhane Military Medical Academy, Ankara, Turkey

Received 4 July 2005 ,Revised 22 December 2005 ,Accepted 30 December 2005.

References 

  1. Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, et al. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988;297:883–887
  2. Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992;327(9):588–593
  3. Cavalli P. False-negative results in Down's syndrome screening. Lancet. 1996;347(6):965–966
  4. Williams KL, Nix BA, Dunstan FD. Effect of screening algorithm, parameter values and median smoothing on patient-specific risk estimates for Down's syndrome screening. Ann Clin Biochem. 2000;37:165–173
  5. Christiansen M, Hogdall EV, Larsen SO, Hogdall C. The variation of risk estimates through pregnancy in second trimester maternal serum screening for Down's syndrome. Prenat Diagn. 2002;22(5):385–387
  6. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986;7;1(8493):1287–93.
  7. Holding S. Biochemical screening for Down's syndrome. BMJ. 1991;302:1275
  8. Benn PA, Collins R. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem. 2001;38:28–36
  9. Reynolds T. Practical problems in Down syndrome screening: what should I do about gestation dating? What is effect of laboratory imprecision. Commun Lab Med. 1992;1:31–38
  10. Zarr JH. Biostatistical Analysis. In: third ed.. New Jersey: Prentice Hall; 1996;p. 38
  11. MacRae AR, Gardner HA, Allen LC, Tokmakejian S, Lepage N. Outcome validation of the Beckman Coulter access analyzer in a second-trimester Down syndrome serum screening application. Clin Chem. 2003;49(1):69–76
  12. Cuckle H, Densem J, Wald N. Repeat maternal serum testing in multiple marker Down's syndrome screening programmes. Prenat Diagn. 1994;14(7):603–607
  13. Muller F, Thalabard JC, Ngo S, Dommergues M. Detection and false-positive rates of maternal serum markers for Down syndrome screening according to maternal age in women over 35 years of age. A study of the agreement of eight dedicated software packages. Prenat Diagn. 2002;22(5):350–353

PII: S0020-7292(06)00003-8

doi: 10.1016/j.ijgo.2005.12.026

International Journal of Gynecology & Obstetrics
Volume 93, Issue 1 , Pages 28-32 , April 2006

Article Tools

* Image Usage & Resolution